PURE Bioscience (OTCMKTS:PURE) issued its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.02), Bloomberg Earnings reports. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.65 million. PURE Bioscience had a negative net margin of 388.83% and a negative return on equity of 252.43%.

Shares of PURE Bioscience (OTCMKTS PURE) opened at $1.00 on Friday. PURE Bioscience has a 12-month low of $0.75 and a 12-month high of $1.36.

Separately, ValuEngine downgraded shares of PURE Bioscience from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th.

WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/pure-bioscience-pure-posts-quarterly-earnings-results-misses-expectations-by-0-02-eps/1767514.html.

PURE Bioscience Company Profile

PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).

Earnings History for PURE Bioscience (OTCMKTS:PURE)

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with Analyst Ratings Network's FREE daily email newsletter.